SEC 13F Intelligence

Fayez Sarofim & Co / ABT

Fayez Sarofim & Co’s Abbott Laboratories Position

Does Fayez Sarofim & Co own Abbott Laboratories (ABT)? Yes — 4.28M shares worth $440M (+1.12% of its 13F portfolio) as of Q1 2026, down from 4.48M shares the prior filed quarter.

Position Value
$440M
Q1 2026
Shares
4.28M
% of Portfolio
+1.12%
Quarters Held
30
currently held

Position History ABT

Reported value by quarter
Q4 ’18: $274MQ4 ’18Q1 ’19: $304MQ2 ’19: $313MQ3 ’19: $315MQ4 ’19: $319MQ4 ’19Q1 ’20: $291MQ2 ’20: $397MQ3 ’20: $489MQ4 ’20: $496MQ4 ’20Q1 ’21: $543MQ2 ’21: $527MQ3 ’21: $563MQ4 ’21: $667MQ4 ’21Q1 ’22: $542MQ2 ’22: $495MQ3 ’22: $439MQ4 ’22: $469MQ4 ’22Q1 ’23: $413MQ2 ’23: $429MQ3 ’23: $417MQ4 ’23: $451MQ4 ’23Q1 ’24: $458MQ2 ’24: $429MQ3 ’24: $478MQ4 ’24: $533MQ4 ’24Q1 ’25: $618MQ2 ’25: $619MQ3 ’25: $609MQ4 ’25: $561MQ4 ’25Q1 ’26: $440Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 20264.28M$440M+1.12%
Q4 20254.48M$561M+1.35%
Q3 20254.52M$609M+1.41%
Q2 20254.52M$619M+1.49%
Q1 20254.62M$618M+1.54%
Q4 20244.68M$533M+1.30%
Q3 20244.19M$478M+1.21%
Q2 20244.13M$429M+1.16%
Q1 20244.03M$458M+1.36%
Q4 20234.03M$451M+1.38%
Q3 20234.30M$417M+1.41%
Q2 20233.93M$429M+1.50%
Q1 20234.08M$413M+1.45%
Q4 20224.27M$469M+1.73%
Q3 20224.54M$439M+1.74%
Q2 20224.56M$495M+1.81%
Q1 20224.58M$542M+1.71%
Q4 20214.74M$667M+2.00%
Q3 20214.76M$563M+1.86%
Q2 20214.55M$527M+1.77%
Q1 20214.53M$543M+2.00%
Q4 20204.53M$496M+1.90%
Q3 20204.49M$489M+2.09%
Q2 20204.35M$397M+1.83%
Q1 20203.68M$291M+1.79%
Q4 20193.67M$319M+1.54%
Q3 20193.76M$315M+1.62%
Q2 20193.72M$313M+1.62%
Q1 20193.81M$304M+1.61%
Q4 20183.79M$274M+1.65%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Fayez Sarofim & Co’s full portfolio or all institutional holders of ABT.